Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Collectin liver 1 (CL-L1, encoded by the COLEC10 gene) is a **soluble pattern recognition protein** of the collectin family, specifically a **C-type lectin** that contains collagen-like sequences and carbohydrate recognition domains[6][8]. CL-L1 plays a key role in the **lectin complement pathway**, contributing to the recognition and removal of pathogens and regulation of cell migration during embryonic development—especially of neural crest cells, with implications for facial, cranial, and other tissue morphogenesis[1][3][8]. Mutations in COLEC10 cause **3MC syndrome**, a disorder with diverse developmental defects[1][3][8]. Recent research suggests that CL-L1 also has **tumor suppressor functions** in hepatocellular carcinoma by inhibiting cell proliferation, migration, and EMT, likely via PI3K-AKT, Hedgehog, and p53 signaling pathways[2]. While it is essential for several physiological processes, CL-L1 is not considered a classical drug target (such as a receptor or enzyme), but may serve as a **prognostic biomarker for cancer** and a molecular marker of certain rare genetic syndromes[2][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Collectin liver 1 (CL-L1).